AIM CONCEPT INTEGRATION
3rd Year MBBS
Cardiovascular System
3rd Year MBBS
Cardiovascular System
“`
Cardiovascular Risk, Lipoproteins and Atherosclerosis
A rapid integration of lipoprotein metabolism, cardiovascular risk, atherosclerotic plaque formation, lipid-lowering therapy and prevention of coronary artery disease.
“`
1. THE TOPIC IN ONE CONNECTED FLOW
“`
Cardiovascular disease develops through interaction between circulating lipoproteins and modifiable or non-modifiable risk factors. Excess atherogenic lipoproteins enter the arterial wall, trigger inflammation and form plaques. Plaque growth or rupture then produces ischemic cardiovascular events. Risk assessment, lipid-lowering therapy and population-based prevention interrupt this process at different stages.
1. Risk and Dyslipidemia
Age, family history, smoking, hypertension, diabetes, obesity and inactivity combine with primary or secondary dyslipidemia.
→
2. Lipoprotein Imbalance
Increased LDL or triglyceride-rich particles, or reduced HDL increases the delivery and retention of cholesterol in arteries.
→
3. Endothelial Injury
Risk factors cause endothelial dysfunction → LDL enters the intima, becomes modified and promotes monocyte adhesion.
→
4. Plaque Formation
Macrophages ingest lipid → foam cells and fatty streak → smooth-muscle migration and collagen deposition form a fibrous plaque.
→
5. Clinical Disease
Progressive stenosis causes chronic ischemia, while plaque rupture or erosion exposes thrombogenic material and causes acute thrombosis.
→
6. Risk Reduction
Risk stratification guides lifestyle modification, blood-pressure and diabetes control, smoking cessation and lipid-lowering therapy.
→
7. Improved Outcome
Lower atherogenic lipid exposure and better risk-factor control → slower plaque progression and fewer myocardial infarctions, strokes and cardiovascular deaths.
“`
2. KEY CLINICAL CONNECTIONS
“`
Lipoproteins and Plaque Risk
Chylomicrons carry dietary triglyceride → remnants are cleared by the liver.
VLDL carries endogenous triglyceride → becomes IDL and then LDL.
LDL delivers cholesterol to tissues and arterial walls → promotes atherosclerosis, whereas HDL supports reverse cholesterol transport → generally relates to lower risk.
Plaque Morphology and Consequences
Fatty streak → foam-cell accumulation → early visible lesion.
Fibrous cap over a lipid-necrotic core → stable narrowing or plaque complication. Rupture, erosion or intraplaque haemorrhage → thrombosis, embolization, infarction or weakening of the arterial wall with aneurysm formation.
Lipid-Lowering Drugs
Statins inhibit HMG-CoA reductase → markedly reduce LDL and cardiovascular events → myopathy and liver-enzyme elevation are important cautions.
Fibrates increase triglyceride clearance → mainly reduce triglycerides → myopathy risk rises when combined with some statins.
Ezetimibe, bile-acid sequestrants and niacin reduce intestinal cholesterol entry, increase bile-acid use or reduce hepatic VLDL production → improve selected lipid abnormalities, but gastrointestinal effects, drug-binding interactions or flushing may limit use.
Risk Stratification and Prevention
Multiple risk factors → higher total cardiovascular risk than any single factor alone → greater need for intensive prevention.
Primary prevention acts before a cardiovascular event, while secondary prevention follows established coronary disease and requires stricter control of lipids, smoking, blood pressure, diabetes, diet and physical inactivity.
“`
3. AIM HIGH-YIELD INTEGRATION REVIEW
“`
⭐ 1. Increased LDL exposure + endothelial dysfunction → cholesterol retention in the intima → inflammation, foam-cell formation and atherosclerotic plaque.
⭐ 2. A thick fibrous cap usually produces a more stable stenotic plaque, whereas a thin inflamed cap is more likely to rupture → acute thrombosis and infarction.
3. Dyslipidemia may be primary or secondary and may appear as raised LDL, raised triglycerides, mixed elevation or reduced HDL → treatment depends on the dominant abnormality and total cardiovascular risk.
⭐ 4. Statin-mediated inhibition of cholesterol synthesis → increased hepatic LDL-receptor activity → major LDL reduction and lower coronary-event risk; interacting drugs can increase statin concentration and myopathy risk.
5. Fibrates mainly lower triglycerides, ezetimibe lowers intestinal cholesterol absorption, bile-acid sequestrants increase cholesterol conversion to bile acids and niacin reduces hepatic VLDL production → each class has a different lipid-profile effect and caution.
6. Bile-acid sequestrants can bind other medicines in the intestine → reduced drug absorption; separating administration times reduces this interaction.
⭐ 7. Smoking, hypertension, diabetes and abnormal lipids cluster in individuals and communities → accelerated atherosclerosis and a high burden of coronary disease and stroke globally and in Pakistan.
8. Cardiovascular risk varies with age, sex, genetics, culture, socioeconomic conditions and access to prevention → risk stratification supports targeted primary prevention and more intensive secondary prevention after established disease.
AIM Exam Trap
Fatty streak does not automatically produce symptoms. Clinical ischemia usually appears after significant plaque narrowing or after an unstable plaque ruptures and produces thrombosis.
“`